Year-end Sale % OFF 
Abstract
CryoLife has developed a method for cryopreserving allograft heart valves for transplantation. Since 1984, 6,907 valves have been processed and 4,216 transplanted. Documentation was available on 2,647 transplants, 11 of which were removed for structural deterioration and 13, for nonstructural deterioration. At the end of 35 months, actuarial survival was 99.17% and the estimated freedom from reoperation, 97.16%. There have been no reports of thromboembolism or valve-related death.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
